logo
Plus   Neg
Share
Email

MacroGenics Shares Surge On Positive Margetuximab Data

MacroGenics, Inc. (MGNX) announced positive results from SOPHIA, the company's Phase 3 clinical study of margetuximab in HER2-positive metastatic breast cancer patients. MacroGenics anticipates submitting a Biologics License Application (BLA) to the U.S. Food and Drug Administration in the second half of 2019.

In Wednesday pre-market trade, MGNX is trading at $23.52, up $12.41 or 111.70 percent.

Margetuximab is an investigational immune-enhancing monoclonal antibody derived from the Company's proprietary Fc Optimization technology platform. The SOPHIA clinical trial met the primary endpoint of prolongation of progression-free survival or PFS in patients treated with the combination of margetuximab plus chemotherapy compared to trastuzumab plus chemotherapy. Patients in the margetuximab arm experienced a 24% risk reduction in PFS compared to patients in the trastuzumab arm (HR=0.76, p=0.033).

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Online retail giant Amazon.com Inc. (AMZN) is reportedly opening a new line of grocery stores separate from its existing Whole Foods and Amazon Go chains. According to CNET, an Amazon spokesperson confirmed that, "Amazon is opening a grocery store in Woodland Hills in 2020." Woodland Hills is a neighborhood... Google Stadia, the tech giant's game streaming service that was unveiled in June, has announced it will launch 12 games on November 19. To celebrate the start of holiday season, coffee retail giant Starbucks Corp. (SBUX) is offering a Happy Hour deal on Thursday, November 14. On November 14 from 2-7 p.m., Starbucks customers can buy one, get one free on any handcrafted beverage, including holiday beverages, size grande or larger. Starbucks...
Follow RTT
>